logo oncology-news

Онкология  >  Новости онкологии

При финансовой поддержке logo MSD Oncology

Multiple myeloma: daratumumab combination significantly improves OS in transplant-ineligible patients

40% reduction in risk for death vs bortezomib, melphalan, and prednisone alone.